Can cyberknife treat about 50 cysts in liver in conjuction w/ chimotherapy? Cancer spread to liver from colon?

This seems like a question to ask your doctor . .however . . probably not as the use of cyberknife depends on the size of the tumors and their shape . . not everyone is a candidate for this type of treatment. Still . .there is no reason why you cannot bring this up for discussion with your doctor.

Today in one of our support groups someone posted the following about radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy (which has a similaritie to cyberknife). You might want to check on this to see if you would be a candidate:

Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):13-23. Links
Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere
brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology
consortium.

Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A
3rd, Espat J, Bilbao JI, Sharma
RA, Thomas JP, Coldwell D.
Wake Radiology Oncology, Cary, NC, USA.\


PURPOSE: To standardize the indications, techniques, multimodality treatment approaches, and
dosimetry to be used for yttrium-90 (Y90) microsphere hepatic brachytherapy.

METHODS AND MATERIALS:
Members of the Radioembolization Brachytherapy Oncology Consortium met as an independent group of
experts in interventional radiology, radiation oncology, nuclear
medicine, medical oncology, and surgical oncology to identify areas of consensus and controversy and to
issue clinical guidelines for Y90 microsphere brachytherapy.

RESULTS: A total of 14recommendations are made with category 2A consensus. Key findings include the following. Sufficient evidence exists to support the safety and
effectiveness of Y90 microsphere therapy. A meticulous angiographic technique is required to prevent
complications. Resin microsphere prescribed activity is best estimated by the body surface area
method. By virtue of their training, certification, and contribution to Y90 microsphere treatment
programs, the disciplines of radiation oncology, nuclear medicine, and interventional radiology are
all qualified to use Y90 microspheres. The panel strongly advocates the creation of a treatment
registry with uniform reporting criteria. Initiation of clinical trials is essential to further
define the safety and role of Y90 microspheres in the context of currently available therapies.

CONCLUSIONS: Yttrium-90 microsphere therapy is a complex procedure that requires multidisciplinary
management for safety and success. Practitioners and cooperative groups are encouraged to use these
guidelines to formulate their treatment and dose-reporting policies.
PMID: 17448867 [PubMed - indexed for MEDLINE]